[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574836":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":34,"collaborators":7,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":48,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Emanuela Ottaviani, MD","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","0039 0512144055","emanuela.ottaviani@aosp.bo.it",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola","RECRUITING","Bologna","40138","Italy","IT",{"type":26,"coordinates":27},"Point",[28,29],11.33875,44.49381,{"lat":29,"lon":28},[32],{"name":10,"role":14,"phone":33,"phoneExt":7,"email":16},"00390512144055",{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100574836","molecular-characterization-of-patients-with-acute-myeloid-leukemia-and-the-impact-of-clonal-evolution-in-the-response-to-therapeutic-treatments-100574836",false,"NCT06764459","Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments","CLEV-LAM-2022","Inclusion Criteria:\n\n* FLT3 mutated\n\nExclusion Criteria:\n\n* Respoder to therapy","ALL","18 Years",{"count":46,"type":47},20,"ESTIMATED","3 Years","OBSERVATIONAL","This study aims to analyze patients with mutated FLT3 AML treated with specific therapy by means of molecular characterization methods, to identify the presence of clones and subclones at onset and to be able to follow their evolution during therapeutic treatment.",[52],"Myeloid Leukemia, Acute",[54,55,56],"AML","FLT3","single cell sequencing","2025-01-29",{"date":59,"type":60},"2025-01-30","ACTUAL",{"date":62,"type":60},"2023-03-15",{"date":64,"type":47},"2026-12-31",{"name":5,"class":6},1]